The current limitations of cancer diagnosis and molecular profiling based on invasive tissue biopsies or clinical imaging have led to the development of the liquid biopsy field. Liquid biopsy includes the isolation of circulating tumor cells (CTCs), circulating free or tumor DNA (cfDNA or ctDNA), extracellular vesicles (EVs), and tumor-educated platelets (TEPs) from body fluid samples and their molecular characterization to identify biomarkers for early cancer diagnosis, prognosis, therapeutic prediction, and follow-up. These innovative biosources show similar features as the primary tumor from where they originated or interacted. This review describes the different technologies and methods used for processing these biosources as well as their main clinical applications with their advantages and limitations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263091 | PMC |
| http://dx.doi.org/10.1101/cshperspect.a037333 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potential Effect of Extracellular Vesicles in Clinical Settings of Lymphoma.
Indian J Clin Biochem
January 2025
Department of Biochemistry, All India Institute of Medical Sciences Rishikesh, Rishikesh, 249203 India.
Liquid biopsy is gaining importance in oncology in the age of precision medicine. Extracellular vesicles (EVs), among other tumor-derived indicators, are isolated and analysed from bodily fluids. EVs are secreted by both healthy and cancerous cells and are lipid bilayer-enclosed particles that are diverse in size and molecular makeup.
View Article and Find Full Text PDFTargeted detection of sequence variants in cell-free DNA from cerebrospinal fluid in pediatric central nervous system tumors.
Front Oncol
January 2025
Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
The emergence of liquid biopsy technologies holds great promise in the cancer setting, including in pediatric central nervous system (CNS) tumors. In contrast to broad lower-depth sequencing, commonly referred to as low pass whole genome sequencing (WGS), targeted platforms with a higher depth of coverage have also been established. Here, we review targeted liquid biopsy techniques with applicability to pediatric CNS tumors.
View Article and Find Full Text PDFVisualization using NIPTviewer support the clinical interpretation of noninvasive prenatal testing results.
BMC Med Genomics
January 2025
Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, SE-751 85, Sweden.
Background: Noninvasive prenatal testing (NIPT) is increasingly used to screen for fetal chromosomal aneuploidy by analyzing cell-free DNA (cfDNA) in peripheral maternal blood. The method provides an opportunity for early detection of large genetic abnormalities without an increased risk of miscarriage due to invasive procedures. Commercial applications for use at clinical laboratories often take advantage of DNA sequencing technologies and include the bioinformatic workup of the sequence data.
View Article and Find Full Text PDFSmall Cell Lung Cancer Unveiled: Exploring the Untapped Resource of Circulating Tumor Cells-Derived Organoids.
Crit Rev Oncol Hematol
January 2025
Institute of Biomedicine of Seville (IBiS), HUVR, CSIC, University of Seville, 41013 Seville, Spain; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), 28029 Madrid, Spain. Electronic address:
Small cell lung cancer (SCLC) remains a challenge in oncology due to its aggressive behavior and dismal prognosis. Despite advances in treatments, novel strategies are urgently needed. Enter liquid biopsy-a game-changer in SCLC management.
View Article and Find Full Text PDFPlasma amino acid profiles of dogs with the hepatocutaneous syndrome and dogs with other chronic liver diseases.
J Vet Intern Med
January 2025
Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA.
Background: Dogs with hepatocutaneous syndrome (HCS) have marked plasma hypoaminoacidemia, but its occurrence in dogs with chronic liver diseases not associated with HCS (non-HCS CLD) is unknown.
Objectives: To determine if plasma hypoaminoacidemia occurs in dogs with non-HCS CLD, compare plasma amino acid (PAA) profiles between dogs with non-HCS CLD and HCS, and define a sensitive and specific PAA pattern for diagnosing HCS.
Animals: Data were collected from client-owned dogs, a prospective cohort of 32 with CLD and 1 with HCS, and a retrospective cohort of 7 with HCS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!